Delcath Systems (NASDAQ:DCTH) CEO Gerard Michel Buys 11,500 Shares of Stock

Delcath Systems, Inc. (NASDAQ:DCTH) CEO Gerard Michel purchased 11,500 shares of the business’s stock in a transaction that occurred on Tuesday, November 11th. The stock was bought at an average cost of $8.53 per share, with a total value of $98,095.00. Following the acquisition, the chief executive officer owned 330,834 shares in the company, valued at $2,822,014.02. This represents a 3.60% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Delcath Systems Trading Up 5.3%

DCTH stock traded up $0.46 during midday trading on Friday, reaching $9.07. The stock had a trading volume of 248,583 shares, compared to its average volume of 651,427. Delcath Systems, Inc. has a 52-week low of $8.33 and a 52-week high of $18.23. The company has a market cap of $320.12 million, a price-to-earnings ratio of 181.68 and a beta of 0.81. The company’s fifty day simple moving average is $10.55 and its 200 day simple moving average is $12.17.

Delcath Systems (NASDAQ:DCTH) last released its quarterly earnings data on Tuesday, November 4th. The company reported $0.02 EPS for the quarter, meeting analysts’ consensus estimates of $0.02. The company had revenue of $20.56 million during the quarter, compared to the consensus estimate of $23.22 million. Delcath Systems had a net margin of 3.18% and a return on equity of 6.91%. Sell-side analysts predict that Delcath Systems, Inc. will post -0.79 EPS for the current year.

Hedge Funds Weigh In On Delcath Systems

A number of large investors have recently made changes to their positions in the stock. Principal Financial Group Inc. lifted its stake in shares of Delcath Systems by 2.1% during the first quarter. Principal Financial Group Inc. now owns 117,620 shares of the company’s stock valued at $1,497,000 after buying an additional 2,437 shares during the period. Baader Bank Aktiengesellschaft increased its holdings in Delcath Systems by 46.7% during the 1st quarter. Baader Bank Aktiengesellschaft now owns 24,903 shares of the company’s stock worth $317,000 after purchasing an additional 7,925 shares during the last quarter. Vanguard Group Inc. grew its stake in Delcath Systems by 13.8% in the first quarter. Vanguard Group Inc. now owns 1,394,028 shares of the company’s stock worth $17,746,000 after purchasing an additional 169,260 shares in the last quarter. Private Wealth Advisors LLC acquired a new position in Delcath Systems in the first quarter worth $1,085,000. Finally, Invesco Ltd. acquired a new stake in Delcath Systems during the first quarter worth about $5,084,000. Hedge funds and other institutional investors own 61.12% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on DCTH shares. Canaccord Genuity Group reaffirmed a “buy” rating and set a $21.00 price objective on shares of Delcath Systems in a research report on Tuesday, October 21st. Stephens dropped their target price on shares of Delcath Systems from $25.00 to $18.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 5th. BTIG Research reaffirmed a “buy” rating and set a $23.00 price objective on shares of Delcath Systems in a report on Tuesday, November 4th. HC Wainwright set a $30.00 target price on Delcath Systems and gave the company a “buy” rating in a research report on Monday, October 20th. Finally, Wall Street Zen lowered Delcath Systems from a “buy” rating to a “hold” rating in a research report on Sunday, October 12th. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $22.40.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.